{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.5","upperLimit":"34.0","value":"18.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"}],"units":"Participants"}],"description":"Cumulative incidence of grade II-IV acute GVHD by day 100 after HCT. Acute GVHD organ staging and assessment of overall grade will use standard consensus criteria. The cumulative incidence of acute and chronic GVHD will be estimated, considering malignancy relapse and non-relapse death as competing risk events.","dispersionType":"95% Confidence Interval","groups":[{"description":"Pre-HCT Conditioning, HCT, GVHD Prophylaxis.","id":"OG000","title":"Conditioning/HCT/GVHD Prophylaxis"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"100 days post hematopoietic cell transplant (HCT)","title":"Incidence of Grade II-IV Acute Graft vs. Host Disease (GVHD)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}